CD19 and B-cell non-Hodgkin lymphoma: For instance, 89Zr-labeled anti-ICOS mAbs have been used to monitor the activation, expansion, and tumor retention of CD19-directed CAR T-cells in murine models of B-cell lymphoma (55).